CureScience logo

CureScience

4 Followers

Wires

Funding announcement

CureScience announces patient centric support through Cureosyti program

Grant Opportunities $2,500-$25,000 CureScienceTM Institute is engaged in patient-centric research and development towards the discovery, development and production of novel medicines in a variety of therapeutic areas including but not limited to oncology, immunology and regenerative medicine. CureScienceTM, a 501(c)(3) nonprofit organization, focuses on research and development, patient development and the long term goal of providing quality health care products. CureScienceTM establishes and funds its own programs and also provides grants for other 501(c)(3) organizations engaged in patient care. CureScienceTM is seeking innovative patient engagement proposals that address patient care, patient support and/or patient education. Funding Amounts: Grants will be awarded in the amounts of $2,500-$25,000. The maximum funding amount for each patient engagement grant is up to $25,000. Grant information and applications available at [https://www.curescience.org/grants]

Team announcement

Dr. Boris Reznik of Biorasi and Venvalo Group joins CureScience as Advisor

Dr. Boris Reznik of Biorasi and Venvalo Group joins CureScience as Advisor

CureScienceTM Institute, a San Diego-based 501(c)(3) non-profit organization dedicated to accelerating novel curative therapies, announced today that Dr. Boris Reznik, has joined the organization's Advisory Board. Dr. Reznik is a veteran of multiple startups and has a strong track record of building companies across a diverse set of technologies-based industries with biomedical sciences being one of his primary focuses. Boris Reznik is the Chairman of Venvalo Group, venture value optimization firm. During his career, Dr. Reznik founded and built technology companies into market leaders and successfully dealt with both Fortune 500 and emerging companies as clients and partners. He has been a lead or co-investor in startups and mid-market firms and has participated in M&A transactions ranging from Millions to Billions. Dr. Reznik has a depth of experience in processes and systems – a unique perspective in the drug and device development world. As the Chairman of Biorasi, a global CRO, he led development of novel therapeutics, from filing IND to getting approved NDA, for companies ranging from startups to Big Pharma. "I am delighted to welcome Dr. Reznik to our Advisory Board," said Dr. Shashaanka Ashili, CEO of CureScienceTM Institute. "He brings a unique experience in accelerating drug and device development for life sciences companies. We at CureScienceTM look forward to benefiting from Dr. Reznik's counsel as we work towards developing personalized therapeutic approaches." "CureScienceTM is a nonprofit institute with a strong team of professionals and an agile approach to novel therapeutics development," said Dr. Reznik. "I am impressed by CureScienceTM 's unconventional methodologies to improving patients' lives. With the rapidly changing life sciences industry, partnerships and collaborations are key to advancing science and I look forward to working with the CureScienceTM team on this front." "Dr. Reznik's experience in novel therapeutics development will be valuable to the researchers at CureScienceTM as we navigate the complex world of translating innovations and discoveries into clinical applications," said Dr. Tom Ichim, Director, Clinical Sciences at CureScienceTM. The Institute is committed to developing a preemptive and personalized approaches based on the early diagnosis, immunology, and regenerative medicine. To this end, CureScienceTM is focused on accelerating research and development programs internally and through the establishment of strategic partnerships with academic and industry partners. More information on CureScience at [www.CureScience.org] More information on Boris Reznik at [www.venvalo.com] [https://www.prnewswire.com/news-releases/curescience-institute-names-dr-boris-reznik-as-advisory-board-member-301233633.html]

Product announcement

Advancing healthcare through co-creation

Advancing healthcare through co-creation

With a philosophy of “cocreate, not compete,” the Sorrento Valley-based nonprofit CureScience Institute is working to advance health care treatments that are more personalized to the patient. CureScience started with a focus on brain cancer research. It is now supporting work to develop curative therapies for cancer, immune and neurological disorders, in addition to using regenerative medicine to cure many different types of human health issues. “We expanded the mission and vision,” said Shashaanka Ashili, CureScience’s CEO. “Now we are looking to develop the framework where we can look into multiple disorders, multiple diseases.” He said a key component of that goal is developing a more holistic approach to putting vast quantities of data to use. “Google has some data, Apple has some data, Facebook has some data, some others have some data,” Ashili said. “Then you have the whole health care system which also has its own silos. Is it time to ask, can we put all these things together? And if so, how?” He added, “The resounding answer to that is yes. That time was yesterday.” The scope of CureScience’s work also includes COVID-19, which has killed more than 1 million people worldwide with vaccines still in development. “By March it struck us all that nobody’s escaping COVID,” Ashili said. “It’s going to disrupt every business and it’s going to change everything.” CureScience’s active mesenchymal stem cell research program could have implications for COVID-19 treatments, and could also yield insights into treating Alzheimer’s disease, which still has no effective treatments that can reverse symptoms. Other unmet patient needs that CureScience would like to address include noninvasive ways to diagnose and monitor the treatment of brain tumors. The institute is also supporting immunotherapy, in which the body’s immune system can be better deployed to fight cancer. The institute is also working in many other areas to bring about more “patient-driven” ways to improve health care. “In the next two years, we should have a framework where we can say this is what patient-driven health care looks like,” Ashili said, adding that the framework also has to showcase the value to patients. “Once we have that, the sky is the limit,” he continued. To help advance its work, CureScience is holding a virtual donor gala on Nov. 21. The event will feature an auction and guest speakers. The institute is located at 10225 Barnes Canyon Road. For more information, visit curescience.org [https://www.delmartimes.net/news/health-science/story/2020-10-27/curescience-ceo-wants-to-cocreate-not-compete-to-advance-health-care]

Team announcement

Dr. Marincola joins CureScience Advisory Board

Dr. Marincola joins CureScience Advisory Board

CureScience™ Institute, a San Diego-based 501(c)(3) non-profit institute dedicated to accelerating novel curative therapies, is pleased to announce that Francesco Marincola, M.D. will join the Advisory Board. "We're honored to have Dr. Francesco Marincola on the advisory board," said Dr. Shashaanka Ashili, CEO of CureScience™ Institute. "As a world leader in tumor immunology, tumor microenvironment, and translational research, Dr. Marincola's experience will be invaluable in advancing the CureScience™ mission and positively impacting patients' lives through development of personalized therapeutic approaches," said Dr. Feng Lin, Lead Immunology Scientist at the Institute. Dr. Marincola is currently Chief Scientific Officer and President at Refuge Biotech where he leads the development of a cell therapy platform. Prior to joining Refuge Biotech, he served as a distinguished research fellow and strategist for immune oncology discovery at AbbVie. In addition, Dr. Marincola developed and led a genetic research institute at Sidra Medical and Research Center in Qatar; and served as Chief of the Infectious Disease and Immunogenetics Section in the Department of Transfusion Medicine at the Clinical Center of the NIH in Bethesda. Dr. Marincola received his M.D. from the University of Milan, and completed his surgery training at Stanford University. He has published more than 600 original articles, reviews, editorials, and books. CureScience™ Institute is committed to developing a preemptive and personalized approach to medicine based on early diagnosis, immunology, and regenerative medicine. To this end, CureScience™ is focused on accelerating research and development programs internally and externally through the establishment of strategic partnerships with academic and industry partners. The addition of Dr. Marincola will particularly help drive the immunology program at CureScience™. "CureScience™ has a strong foundation in place with a talented and multidisciplinary team of scientists," said Dr. Marincola. "I'm excited to join as a member of the advisory board working with researchers to advance the clinical development of novel approaches." For more information at [www.CureScience.org] Media contact: Lawrence D. Jones, Ph.D. CureScience™ Institute (858) 800 CURE (2873) [https://www.prnewswire.com/news-releases/curescience-institute-announces-dr-franco-marincola-as-new-advisory-board-member-301123939.html]

Team announcement

The CureScience Institute appoints Gary Shields to Advisory Board

The CureScience Institute appoints Gary Shields to Advisory Board

Venture capitalist Gary Shields has been added to the Advisory Board of medical non-profit, The CureScience Institute. Mr. Shields brings expertise to help guide CureScience’s focus on providing therapies based on data- and patient-centric approaches, as well as a new need for COVID-19 treatments. "Data-centricity and patient-centricity are the core tenants of our mission and vision. Our three-pronged approach of bringing innovations, patient engagement, and care management is essential to realize the goals of precision medicine," said CureScience Interim CEO Dr. Shashaanka Ashili. "Gary brings decades of venture capital experience, and his insights would be instrumental in fostering relationships with innovators." Mr. Shields is the founder of venture capital company Avtech Ventures, and co-founder of investment bank Flemming Lessard & Shields. An experienced investment banker, he brings more than 30 years of experience in capitalization, investment and transactions. "The Institute's unique value of empowering the patients by making them the stakeholders within the ecosystem is very promising and exciting," said Mr. Shields. "Working with startups and building a translational ecosystem is critical to achieving the goals of precision medicine."

Other announcement

BCRI expands mission and vision

SAN DIEGO, July 16, 2020 /PRNewswire/ -- The CureScience™ Institute, a non-profit organization, focused on the acceleration of curative therapies for unmet needs, announced today a strategic expansion of its vision and mission. The Institute's initial focus was on translational research in oncology and neurological disorders. Based on recent successes, the Board of Directors has decided to strategically expand the Institute's vision to leverage early diagnostics, regenerative medicine, and immunotherapy to enable a new generation of precision medicines. The Institute is expanding research activities with a strategic focus on establishing transdisciplinary ThinkTanks to bring thought-provoking ideas to the forefront and to accelerate therapeutic and translational research by developing a collaborative ecosystem of academic, industry, and patient-centric stakeholders. The focus will be on exploring "out of the box" solutions to address the bottlenecks in clinical translation and unmet needs in the delivery of care. Crucially, the Institute will be the catalyst that is needed to establish feasibility and clinical implementation models of these new ideas. In addition to autoimmune and neurological disorders, different disorders will be adopted to explore solutions through transdisciplinary approaches. Strategically the Board of Directors chose to adopt COVID-19 as the current disorder theme due to its global impact. "I am proud to be part of this initiative, where the focus is on developing therapies through transdisciplinary approaches. The two key pieces, 'ThinkTanks' and 'Disorder themes,' are unique to our approach in addressing unmet needs," said Dr. Shashaanka Ashili. Regardingclinical implementation models, the Institute will engage patients and focus on developing patient engagement models to support the "disorder themes." As a core focus, the Institute will be working with startups and other corporate stakeholders. The goals of this initiative are to enable novel technologies to strengthen early diagnosis and build a pipeline of patient-centric therapeutic repositories. The Institute has already participated in enabling startups with a focus on establishing a pipeline of cancer therapeutics. To accomplish its mission, the Institute has expanded its Board of Advisors recruiting international scientists, including Dr. Jocopo Annese, founder of The Brain Observatory. "The Institute's approach of rapidly redirecting resources and orchestrating ThinkTanks towards priority focus areas is novel and unique in biomedical research. As a member of the Advisory Board, I am looking forward to contributing to this important challenge," said Dr. Jacopo Annese More information at www.CureScience.org [https://www.prnewswire.com/news-releases/curescience-institute-expands-vision-and-advisory-board-to-accelerate-innovation-301095253.html]

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.